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Polycystic ovary syndrome (PCOS) is one of the most important gynecological disorders among
reproductive-age women. In patients with PCOS, the secretion rate and metabolism of androgens and
estrogens are disrupted. With regards to the increasing prevalence of PCOS and associated physical
and mental problems as well as the effects of changes in sex hormones in development of this disease,
our aim is to investigate the effects of different herbal extracts on changes in the serum levels of sex hor-
mones and ovarian tissue. To conduct this review, an extensive literature search was conducted using,
relevant publications published between 1990 and 2017, and indexed in Google Scholar, PubMed,
Elsevier, Scientific Information Database, and Science Direct were studied. The search terms used to
retrieve the publications were as follows: Herbal medical extract، Names of medicinal plants ،
polycystic ovary syndrome, PCOS, the mechanism of hormone. According to the evidence, herbal extracts
containing phytoestrogens cause decrease in hyperandrogenism, insulin resistance, and ovary weight as
well as increase in ovulation. Therefore, these plants can be partly effective in this syndrome via affecting
the serum levels of different hormones and ovarian weight and morphology, representing an opportunity
to investigate and discovery new bioactive products.
 2018 Middle East Fertility Society. Production and hosting by Elsevier B.V. This is an open access article
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Polycystic ovary syndrome (PCOS) is characterized by endo-
crine, metabolic, and genetic disorders, chronic absence of ovula-
tion of polycystic ovary, and clinical and biochemical
presentations of hyperandrogenism [1]. The symptoms of PCOS
include clinical ones (menstrual disorders, hirsutism, acne, bald-
ness, and infertility), changes in endocrine hormones (increased
levels of androgen, estrogen, and prolactin and decreased level of
progesterone), and metabolic disorders (insulin resistance, dia-
betes, dyslipidemia, and type 2 diabetes). However, in some cases,
estradiol level does not change [2]. In vivo and in vitro studies on
theca cells suggested that ovarian theca cells are much more active
to convert androgenic precursors into testosterone in women with
PCOS than in healthy women. Indeed, Theca cells produce andro-
gen in response to luteinizing hormone (LH); therefore, the blood
levels of androgens increase in people with PCOS [3]. The high
levels of androgens especially testosterone in PCOS, their role in
lack of ovulation, and disrupted synthesis of sex hormones, which
causes clinical symptoms and dysfunction of genital tract in the
patients, are the main reasons for infertility in reproductive-age
women [4,5]. PCOS is one of the most common gynecological dis-
orders in reproductive-age women with the incidence likelihood
of 4–12% [6,7]. The prevalence rate of this disease was reported
5.6–8% in Europe [8,9]. According to the latest studies, the preva-
lence of PCOS in Iran is 19.5% based on Rotterdam criteria and
6.8% based on the NIH criteria [10]. The cause of infertility is lack
of ovulation in approximately 75% of the cases [11]. Currently, clo-
miphene citrate, metformin, and tamoxifen are the most widely
used drugs to treat PCOS [12]. With regards to the side effects of
such drugs and relative treatment of PCOS by them, it is essential
to identify and develop alternative drugs [2], out of which plant-
based drugs especially estrogen-containing ones (phytoestrogens)
are considered to be comparatively more effective [13,14]. Phytoe-
strogens are weak antagonists of estrogen, and exhibit more potent
estrogenic effects when estrogen level of the body is low [15]. With
regards to the increasing prevalence of PCOS and associated phys-
ical and mental problems as well as the effects of changes in sex
hormones in development of this disease, our aim is to review evi-
dence on the pathophysiology and etiology of this disease and the
effects of different herbal extracts on changes in the serum levels
of sex hormones and ovarian tissue.2. Methods
2.1. Database and search strategies
A systematic review of the literature between the periods of
1990–2017 was made based on Google Scholar, PubMed, Elsevier,
Scientific Information Database, and Science Direct. The keywords
used for the search were Herbal medical extract، Names of
medicinal plants ، polycystic ovary syndrome, PCOS ،The
mechanism of hormone.3. The pathophysiology and etiology of PCOS
The cause of PCOS has not yet been definitely determined; how-
ever, it is mainly characterized by hyperandrogenism, infertility,
lack of ovulation [16], increased level of LH [17], increased insulin
resistance, decreased sex hormone-binding globulin (SHBG)
[18,19], and hirsutism [20] which visualized as well as diagnosed
by ultrasonography and laboratory tests [21]. Because of disrupted
secretion rate and metabolism of androgens and estrogens in
women with PCOS, the serum concentrations of androgens such
as testosterone, androstenedione, and dehydroepiandrosteronePlease cite this article in press as: Z. Abasian et al., A review on role of medicina
signaling, therapeutic status and future prospects, Middle East Fertil Soc J (20are most probably high in such women [20,22]. In addition, the
incidence of certain complications such as environmental insulin
resistance and hyperinsulinemia is very likely. Such complications
lead to obesity at different degrees. Insulin resistance can occur
due to impaired signaling pathway of insulin receptor. Therefore,
insulin function in the cell is impaired, which causes further
increase in insulin secretion to compensate for its shortage. With
increase in insulin, the effect of gonadotropins on ovarian function
increases, and adiponectin decreases in patients with PCOS due to
insulin resistance [22]. Insulin resistance and subsequently exces-
sive increase in insulin levels cause the frequency of GnRH to esca-
late, which results in increased LH/FSH. These hormone changes in
the theca cells and granulosa cells (GCs) cause increase in the syn-
thesis of androgens and decrease in the synthesis of estradiol, and
stops the maturation of follicles, leading to impaired ovulation and
therefore development of PCOS [23].4. The role of the neuroendocrine system in PCOS
The reproductive system is a constituent of the endocrine sys-
tem and includes an axis called reproductive axis that is located
at three levels; hypothalamic, pituitary, and gonadal [24], and is
therefore referred to as the hypothalamic–pituitary–gonadal
(HPG) or gonadotropic axis. In this axis, hypothalamus neurons
produce gonadotropin-releasing hormone (GnRH) that enters the
hypophyseal portal system and then stimulates release of gonado-
tropins, luteinizing hormone (LH), and follicle-stimulating hor-
mone (FSH) from the anterior lobe (adenohypophysis) of the
pituitary gland (hypophysis). These hormones affect the gonads
and lead to gametogenesis through producing the sex steroids
estrogen, progestins, and androgens [25]. Sex steroids control sec-
ondary sexual characteristics, and contribute to regulating other
parts of the HPG axis using negative and positive feedback. The
HPG axis is temporarily active during embryonic development,
but then it remains inactive until puberty. During puberty, a series
of developments lead to increased secretion of GnRH from the
hypothalamus. Release of adequate amounts of leptin from adipose
tissue and genetic, environmental, and social conditions are some
of the most important factors for these developments [26]. After
puberty, regulatory signaling such as temperature and light, cer-
tain factors such as blood sugar levels and body metabolism, and
mental states can affect the secretion of GnRH that in turn influ-
ences on gonadotropic cells of adenohypophysis and causes
increase in the secretion of FSH and LH [27]. LH and FSH are both
secreted in a type of cell (hypophyseal gonadotropin) and stored in
separate granules but the rhythm of LH release is compatible with
GnRH pulses [28]. GnRH is the main regulator of sexual maturity
and reproduction in mammals [29]. To date, 20 different types of
GnRH have been identified in vertebrate three main types of which
are GnRH I, II, and III. In mammals, GnRH I and II are secreted.
GnRH I serve as the regulator of gonadotropins and GnRH II acts
as a neuromodulator and also contributes to sexual behaviors
[30]. GnRH is released from the hypothalamus as pulse and surge.
The pulse mode of GnRH represents the coordinated activity of
over 1500 GnRH neurons that comprise a network in the hypotha-
lamus. Each GnRH pulse is accompanied by an LH pulse. In human,
the interval between LH pulses is one hour. This high coordination
among the GnRH neurons is derived from a neuropulse generator
referred to as the GnRH pulse generator [31]. This pulse mode of
the GnRH release is essential for normal functioning of the gonado-
tropins in the long term and the capacity of normal reproduction
[32]. Slow GnRH pulses release further FSH while rapid pulses
are more compatible with increased LH [33]. In normal conditions,
theca cells mainly produce androstenedione under LH influence.
Androstenedione enters GCs and waits for either of these twol plants in polycystic ovarian syndrome: Pathophysiology, neuroendocrine
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beta-estradiol under the influence of 17-beta hydroxysteroid dehy-
drogenase (17b-HSD), under the aromatase CYP19 influence; or it
is converted to testosterone under 7bHSD influence and then
testosterone converted to beta-estradiol under the influence of
aromatase. The expression rate 7bHSD in the GCs is regulated by
FSH effect [17,22]. In the first sexual cycle (the follicular phase),
estradiol leads to formation of further receptors from FSH,
increases the GCs sensitivity to FSH, and also reduces FSH secretion
through exerting negative feedback on the pituitary. But, because
the dominant follicle expresses a great number of the FSH recep-Fig. 1. The prevalence rates of clinical symptoms in women with polycystic ovary
syndrome (PCOS).
Fig. 2. The main pathoge
Please cite this article in press as: Z. Abasian et al., A review on role of medicina
signaling, therapeutic status and future prospects, Middle East Fertil Soc J (201tors, it responses proportionately to the reduced amounts of the
FSH and continues to produce estradiol [22,34]. When estradiol
levels increase, this hormone can exert positive, rather than nega-
tive, feedback on the hypothalamus and lead to a sudden and con-
siderable increase in GnRH secretion, which in turn results in LH
surge, and therefore ovulation occurs [34,35]. Although the cause
of PCOS has not yet been determined, it is obvious that excessive
increase in insulin secretion, which is due to insulin resistance,
can cause increase in the frequency of the GnRH pulses and there-
fore increase in the secretion of LH compared to that of FSH. This
hormonal change at the surfaces of theca and GCs leads to
increased production of the androgens and decreased production
of estradiol that stops follicular maturation and therefore disrupts
ovulation[34] .5. Clinical symptoms of women with PCOS
The prevalence rates, associated clinical symptoms and patho-
genesis in women with PCOS are presented in Figs. 1 and 2 [35,36].5.1. Treatments for PCOS
Weight loss via Diet and Exercise.
Laparoscopy using different methods such as: electrocautery,
laser, and biopsy.
Synthetic drugs:
 Oral contraceptive pills;
 Progestins such as medroxy progesterone acetate;
 Anti-androgens such as cyproterone acetate, spironolactone or
flutamide;
 Insulin-sensitizing drugs (insulin-metformin);
 Clomiphene citrate [36–38].
5.2. Medicinal plants effective on PCOS
See Tables 1 and 2.nic factors in PCOS.
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Table 1
Summarizes evidence on medicinal plants that are effective on PCOS in human (Clinical studies).
Medicalplants
&scientific
name
English
name
Family Study design Study duration Mechanism
of action
Outcomes References
Mentha
spicata
Spearmint Lamiaceae 42 women with PCOS and
hirsutism treated with M.
spicata tea twice a day
compared with placebo tea.
One month Not clear Decreased levels of total and
free testosterone in M. spicata-
treated group after 1-month
treatment, increased FSH and
LH, and decreased degree of
hirsutism
[41]
Cinnamomum
zeylancum
Cinnamon Lauraceae Fifteen women with PCOS orally
treated with C. zeylanicum and
placebo.
For eight weeks Improved
insulin
sensitivity
Significant decrease in insulin
resistance in C. zeylanicum-
treated group.
[48]
Grifola
frondosa
Maitake
or Hen-of-
the-wood
Meripilaceac 72 patients randomly assigned
to the group treated with the
extract or clomiphene citrate
alone and 18 ones who did not
respond were co-treated with
the extract and clomiphene
citrate.
Treatment with the
drug alone for 12
weeks and co-
treatment with the
drug and extract
for 16 weeks.
Improved
insulin
sensitivity
Observation of ovulation in the
patients of all groups
[49]
Origanum
majorana
Sweet
Marjoram
Lamiaceae 25 patients were treated with O.
majorana tea (14 patients) and
placebo tea (11 patients).
For one month Improved
insulin
sensitivity
and
antiandrogen
Decreasing fasting insulin levels
and DHEA-S.
[52]
Trigonella
foenum-
graceum L
Fenugreek Leguminosae 58 women with PCOS assigned
to two groups: One 30 +
individual group treated with T.
foenum-graceum seed capsule +
metformin and the other group
treated with placebo +
metformin.
8 weeks Improved
insulin
sensitivity
According to ultrasound scans,
decrease in the polycystic
ovaries and improvement of the
ultrasound results and
menstrual cycle in the women
[56]
Phoenix
dactylifera
Date palm Arecaceae 48 female Wistar rats assigned
to 6 groups of 8 each: Control
group, sham group administered
with estradiol valerate solvent
for 60 days and then treated
with water for 21 days, PCOS1
control and PCOS2 control
groups.
60-day
administration
with estradiol
valerate and 21-
day treatment with
the extract.
Antiandrogen Decreased levels of estrogen
and LH, increased levels of
progesterone andFSH,
decreased number of cystic
follicles, increased number of
primary and antral follicles and
Graafian such as corpus luteum.
[61]
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We conducted this review to present evidences on the etiology
of PCOS and introduce plants that have been recently investigated
for their effects on this disease in studies with human subjects and
animal models. Most studies investigated the serum levels of sex
hormones, hyperandrogenism, insulin resistance, ovarian weight
and histopathology, ovulation, and the symptoms of PCOS before
and after the treatment. By inducing polycystic ovary syndrome
and then, treatment with different extracts the blood testosterone
and LH levels were reduced and the blood progesterone and FSH
levels increased. Also, histopathological changes indicated that
there were many types of follicles in different stages of growth
in the treatment groups, including primary follicles, antral, peri-
antral, graafian, corpus luteum, and large oocytes. Most of these
studies reported that the studied herbal extracts were effective
in treating PCOS and improved the levels of sex hormones, insulin
resistance, hyperandrogenism, ovulation, and PCOS symptoms. In
these studies, testosterone propionate, estradiol valerate, and
letrozole were used to induce PCOS. In estradiol valerate-induced
PCOS, widely used in studies, LH and testosterone increase and
FSH decreases [45]. Besides that, letrozole, an aromatase inhibitor,
has been used to induce PCOS. Aromatase is a small member of the
cytochrome p450 family that converts androsetenedione to estro-
gen and testosterone to estradiol. Hormone changes in such mod-
els are associated with increased levels of testosterone and LH, and
decreased levels of estrogen, progesterone, and FSH that are in
agreement with PCOS-induced changes in different species [62].Please cite this article in press as: Z. Abasian et al., A review on role of medicina
signaling, therapeutic status and future prospects, Middle East Fertil Soc J (20In women with PCOS, secretion rate and metabolism of androgens
and estrogens are impaired and androgens levels increase. With
development of insulin resistance and subsequently excessive
increase in insulin, the frequencies of GnRH pulses may be esca-
lated. As a result, insulin resistance causes increase in LH/FSH,
and such hormone changes at theca cell surface and granulosa
cause increase in the synthesis of androgens and decrease in the
synthesis of estradiol. Finally, the maturation of follicles is stopped
and therefore ovulation is impaired [63]. Currently, because there
is no definite and ideal treatment for hormonal disorders and asso-
ciated clinical manifestations, and also chemical drugs have several
side effects, thereby alternative treatment, especially phytother-
apy, can be considered instead of commercially available drugs.
Because medicinal plants contain active compounds as well as
has no major adverse effects, therefore, they have attracted much
attention within recent years. For example licorice, raspberry, and
soybean are some of these plants and contains large amounts of
certain phytoestrogens such as biochanin A, daidzein, genistein,
and formononetin. The anti-androgenic property of this plant
causes decrease in androgens levels in patients with PCOS
[39,44,50]. A study demonstrated that raspberry fruit extract
caused decrease in testosterone through inhibiting NF-kB pathway,
and improved ovarian tissue symptoms including the number of
developing follicles, granulosa layer thickness, and the number of
corpus luteum through antioxidant and anti-inflammatory proper-
ties [44]. Jelodar et al. reported that the consumption of V. agnus-
castus fruit extract could cause increase in aromatase activity,
and decrease in testosterone through aromatizing testosteronel plants in polycystic ovarian syndrome: Pathophysiology, neuroendocrine
18), https://doi.org/10.1016/j.mefs.2018.04.005
Table 2
Summarizes evidence on medicinal plants that are effective on PCOS in animals (Experimental studies).
Medical plants &
scientific name
English name Family Study design Study duration Mechanism of
action
Outcomes References
Glycyrrhiza glabra L Licorice Fabaceae 84 mice assigned to six
groups: Control group,
hyperandrogenism group,
and G. glabra extract (150,
300, and 450 mg/kg) groups
Inducing PCOS
using letrozole
for 21 days
Antiandrogen
and
phytoestrogen
Improvement of the
adverse effects of
hyperandrogenism due to
PCOS in female mice’s
fertility.
[39]
Mentha piperita Peppermint Lamiaceae 40 Wistar rats with
letrozole-induced PCOS.
Daily
administration
with letrozole
for three weeks
and treatment
with the extract
for three weeks
Antioxidant
property
M. piperita
supplementation caused
improvement of ovarian
cysts, necrosis of stromal
mesenchymal cells, and
hyperplasia of luminal
epithelial cells.
[40]
Vitex agnus-castus Monk,s
pepper tree
Verbenaceae 32 Sprague Dawley rats
with letrozole-induced
PCOS and the treatment
group treated with 365 mg/
kg of the extract.
28-day
administration
with letrozole
and 30-day
treatment with
the extract
Antiandrogen
and
phytoestrogen
Decreased serum level of
testosterone and
increased serum level of
progesterone
[2]
Marrubium Vulgare White
Horehound
Lamiaceae 48 Wistar rats with
letrozole-induced PCOS and
the treatment group treated
with 500 and 1000 mg/kg of
the extract.
28-day
administration
with letrozole
and 21-day
treatment with
the extract
Antiandrogen
and
phytoestrogen
Significant decrease in LH
and testosterone (in 1000
mg/kg) and in estradiol
and progesterone (at both
doses).
[42]
Camellia sinensis Green Tea Theaceae 96 Wistar rats with
estradiol valerate-induced
PCOS assigned to 4 groups
and the treatment groups
treated with 50, 100, and
200 mg/kg of the extract.
60-day
administration
with estradiol
valerate and 10-
day treatment
with the extract
Antioxidant
property
Significant decrease in
serum LH levels, decrease
in the body’s and ovarian
weight and insulin
resistance; changes in the
number of follicles and
the thickness of theca
layer in
histomorphometric
studies
[43]
Rubus idaeus 
strigosus
Raspberry Rosaceae 120 Wistar rats with
estradiol valerate-induced
PCOS and the treatment
groups treated with 100,
150, and 200 mg/kg of the
extract.
60-day
administration
with estradiol
valerate and 10-
day treatment
with the extract
Antioxidant
property
Decrease in testosterone,
estradiol, LH, and CRP and
increase in progesterone
and FSH
[44]
Chamaemelum nobile
Or Anthemis nobilis
L.
Chamomile Asteraceae 30 rats with estradiol
valerate-induced PCOS and
treated with 25, 50, and 75
mg/kg of the extract.
60-day
administration
with estradiol
valerate and 10-
day treatment
with the extract
Antiandrogen
and
phytoestrogen
Decrease in the
symptoms of PCOS and
the secretion of LH, FSH,
and estradiol.
[45]
Pergularia Daemia Trellis – vine Apocynaceae Inducing PCOS using
testosterone propionate in
Albino Wistar rats and
treating them with the
extract.
One-week
induction and
then one-week
treatment with
the extract
Management
of obesity
Normalization of irregular
estrous cycle in patients
with PCOS after
treatment with the
extract
[46]
Foeniculum vulgare Fennel Apiaceae 30 rats with estradiol
valerate-induced PCOS and
6 normal rats; the
treatment groups were
treated with 250, 500, and
1000 mg/kg of the extract.
60-day
administration
with estradiol
valerate and 10-
day treatment
with the extract
Antiandrogen
and
phytoestrogen
Increased concentration
of FSH after treatment
with 500 and 1000 mg/kg
of the extract and
decreased LH and
testosterone after
treatment with 1000 mg/
kg of the extract.
[47]
Glycine max Soybean Fabaceae Inducing PCOS in Sprague
Dawley rats using letrozole
and treating them with
soybean isoflavones (in
50&100 mg/kg).
21-day
administration
with letrozole
and 14-day
treatment with
the extract
Antiandrogen
and
phytoestrogen
and
antioxidant
100 mg/kg of soybean
significantly changed
PCOS symptoms through
the body’s weight loss,
and reducing diestrus
phase, testosterone, the
activities of 3 beta-
hydroxysteroid
dehydrogenase and
17beta-hydroxysteroid
dehydrogenase, and
oxidative stress.
[50]
Atractylodes
macrocephala Koidz
Atractylodes Asteraceae 60 rats assigned to 5 groups
of 12 each: Healthy control,
Inducing PCOS
for 12 days and
Antiandrogen Improving estrous cycle,
decreasing the plasma
[51]
(continued on next page)
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Table 2 (continued)
Medical plants &
scientific name
English name Family Study design Study duration Mechanism of
action
Outcomes References
(AMK) PCOS, and three PCOS
groups treated with low,
moderate, and high
concentrations of the
extract; inducing PCOS
using testosterone
propionate.
treating with
the extract for 8
consecutive
weeks.
levels of total
testosterone,
androsetenedione, and
FAI, higher levels of FSH
and lower LH/FSH and
anti-Mullerian hormone
in ovary, and decreasing
the expression levels of
FSH receptor and
increasing the expression
levels of aquaporin 9.
Corylus avellana Hazelnut or
cobnut
Betulaceae
Or
Corylaceae
18 Sprague Dawley rats
with letrozole-induced
PCOS assigned to 3 groups
of 6 each: Control,
busereline acetate-treated,
and treatment
21-day
administration
with letrozole
and 45-day
testing of the
groups
Antiandrogen Effective in treating PCOS
through regulating serum
lipid profile, steroids, and
gonadotropins.
[53]
Bmbusa Vulgaria Bamboo Poaceae 4 groups of 6 each
administered with letrozole,
group 2 considered negative
control, and groups 3 and 4
treated with 0.5 and 1 ml/kg
of the extract.
21-day
administration
with letrozole
and 3-week
treatment with
the extract
Antioxidant
and
antidiabetic
Improving estrous cycle
and exerting
hypolipidemic and
hypoglycemic effects.
Decreasing blood glucose
and the levels of
cholesterol, LDL, and
triglyceride, improving
cystic ovaries and
ovulation.
[54]
Aloe vera Aloe,
Barbados aloe
Aloaceae Two groups: Control group
daily treated with
carboxymethyl cellulose 1%
and the other group
administered with letrozole
to induce PCOS and then
treated with nonpolar A.
vera extract for 60 days.
21-day
administration
with letrozole
and 60-day
treatment with
the extract.
Antiandrogen Decreasing the levels of
testosterone and insulin
through improving the
levels of progesterone and
estradiol; decreasing the
transcription levels of
steroid receptors;
increasing aromatase
expression.
[55]
Labisia pumila var.
alata
Labisia Primulaceae Mice with PCOS assigned to
two groups: The extract-
treated and control groups;
the extract-treated group
orally treated with 50 mg/
kg of the extract each day
and the control group
treated with 1 ml of
deionized water.
4–5 weeks Antiandrogen
and
phytoestrogen
Increasing uterus weight
and insulin resistance;
increasing resistin and
improving lipid profile; in
adipose tissue, decreasing
the expression of leptin
mRNA but ineffective on
the expression of resistin
and adiponectin.
[57]
Heracleum persicum Desf Apiaceae In 30 rats, PCOS was
induced by estradiol
valerate and then treated
with doses of 200 mg/kg,
400 and 800 Desf extracts.
Induction of
PCOS in 60 days
and 10 days
treatment with
extract.
Antiandrogen Serum levels of estradiol,
testosterone and LH
increased, and FSH
increased.
[58]
Cocos nucifera Coconut palm Arecaceae Wistar rats with letrozole-
induced PCOS were left
untreated for 21 days and
then treated with 100 and
200 mg/kg of C. nucifera
aqueous extract. A positive
control group, a negative
control group, and two
treatment groups were
studied.
21-day
administration
with letrozole
and 4-week
treatment with
the extract.
Antiandrogen
and
phytoestrogen
Regulating estrous cycle
and increasing uterus
weight.
[59]
Punica granatum L. Pomegranate
Juice
Lythraceae 56 Wistar rats were
assigned to 6 groups of 8
each and PCOS was induced
by estradiol valerate. The
rats were treated with
different doses of P.
granatum extract.
81 days Antioxidant
property
Improving the levels of
testosterone,
androsetenedione, and
estrogen in the treated
groups.
[60]
6 Z. Abasian et al. /Middle East Fertility Society Journal xxx (2018) xxx–xxxand converting it into estradiol. This extract contains a number of
phytoestrogens. Certain flavonoids such as apigenin, vitexin, and
penduletin that can bind to estrogen receptors were isolated from
this plant [2]. Isoflavones exert their inhibitory effects on many key
enzymes of steroid metabolism and therefore decrease the levels ofPlease cite this article in press as: Z. Abasian et al., A review on role of medicina
signaling, therapeutic status and future prospects, Middle East Fertil Soc J (20active hormones in the tissues in question. Many cancers of
reproductive organs are dependent on hormones, and cell growth
is prevented by decrease in the levels of active hormones. This
can be an explanation for isoflavones’ having potential to exhibit
phytoestrogen activities through steroid pathway. As a result, anl plants in polycystic ovarian syndrome: Pathophysiology, neuroendocrine
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Z. Abasian et al. /Middle East Fertility Society Journal xxx (2018) xxx–xxx 7isoflavone-rich diet can be the biochemical basis of preventive
effects against cancer [64]. Other studies indicated that genistein
could inhibit 3b-HSD and 17b-HSD in the testicular microsomes
of both human and mouse. It has been reported that isoflavonoids
due to having phenolic ring preferably inhibit the activities of 3b-
HSD and 17b-HSD. In addition to inhibiting steroid-synthesizing
enzymes, genistein can be involved in LH receptor’s binding to G-
protein, and affect adenylatecyclase activity if LH receptor does
not bind to the G-protein and block steroidogenesis-stimulated
production of LH [50]. Oxidative stress is considered a pathological
characteristic of PCOS, and in women with PCOS, total antioxidant
status declines. Evidence indicates that the levels of ROS in ovarian
tissue increase in PCOS, causing imbalance between oxidant and
antioxidant systems. Soybean isoflavonoids exert antioxidant
effect because of containing aromatic ring and genistein [50]. P.
dactylifera pollen contains antioxidant compounds such as differ-
ent vitamins and minerals, e.g. zinc and selenium, that cause regu-
lation of the body’s antioxidant balance in people with PCOS (62).
Many of the studied plants including Soybean, Raspberry, A. vera, L.
pumila, C. nucifera, G. max, and G. glabra have anti-androgenic
property and certain plants such as: P dactylifera, G.max, C. sinensis,
M. piperita and T. vulgaris have antioxidant property that are effec-
tive in treating PCOS through improving the serum levels of sex
hormones and decreasing oxidative stress. In the light of the evi-
dence, different types of phytoestrogens and antioxidant com-
pounds found in medicinal plants can improve PCOS symptoms
and therefore be effectively used to treat this syndrome.
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